MPNs | Clinical

The Role of JAK Inhibitors Continues to Evolve to Improve Outcomes in Myelofibrosis

November 10, 2020

In an interview with Targeted Oncology, John O. Mascarenhas, MD, discussed the evolving role of JAK inhibitors for the treatment of patients with myelofibrosis, including new agents under evaluation in randomized studies and potential combination strategies that may also improve outcomes.

New Therapies in Development for Myelofibrosis

October 15, 2020

Building on the transformative impetus from the first FDA-approved JAK 1/2 inhibitor, ruxolitinib, in the clinical landscape of myeloproliferative neoplasms, we are entering a new era of multiple JAK inhibitors and other diverse classes of drugs in rapid clinical development.

Treatment Options Expand Beyond JAK Inhibition for Patients With Myelofibrosis

October 11, 2020

During the National Comprehensive Cancer Network 2020 Virtual Congress: Hematologic Malignancies, Aaron Gerds, MD, MS, reviewed the current treatment landscape for patients with myelofibrosis and what’s to come for the treatment of this patient population as clinical trials continue to advance the field.

Genomic Testing Should Be Standard in Myelofibrosis at Diagnosis, Says Rampal

September 22, 2020

Raajit K. Rampal, MD, PhD, discussed the role of genomics in the treatment landscape of myelofibrosis and the remaining challenges that need to be addressed in order to use this information more effectively to treat patients and improve outcomes.